Pharma Exclusives Pressreleases
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
Tuesday, August 26, 2025Gilead Sciences Inctoday announced that the European Commission EC has granted marketing authorization for Yeytuo lenacapavirthe companys twiceyearly injectable HIV capsid inhibitor
Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
Monday, August 25, 2025H Lundbeck AS Lundbeck today announced that new data regarding bexicaserin a novel treatment under investigation for seizures associated with Developmental and Epileptic Encephalopathies DEEs
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
Monday, August 25, 2025Eisai Co Ltdand Biogen Inc Nasdaq BIIB Corporate headquarters Cambridge Massachusetts CEO Christopher A Viehbacher Biogen announced today that the antiamyloid beta A monoclonal antibody
BioMed X and Novo Nordisk Launch New Collaboration in Oral Peptide Drug Delivery
Tuesday, August 19, 2025BioMed X an independent biomedical research institute based in Heidelberg Germany announced today the launch of a new collaboration with Novo Nordisk a leading global healthcare company headquartered
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
Saturday, August 16, 2025Novo Nordisk today announced that the US Food and Drug Administration FDA has approved an additional indication for Wegovy semaglutide mg based on a supplemental New Drug Application
Hansa Biopharma announces supportive data from treatment with imlifidase prior to the administration of gene therapy for Duchenne muscular dystrophy
Saturday, August 02, 2025Hansa Biopharma AB Hansa Nasdaq Stockholm HNSA today announced topline results from three patients with Duchenne muscular dystrophy DMD treated with Hansas imlifidase prior to receiving Sareptas ELEVIDYS delandistrogene moxeparvovecrokl in the SRP tr...
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
Saturday, August 02, 2025Rocheannounced today new fiveyear efficacy safety and durability data from the Phase III Portal study a longterm extension of the Phase III Archway study of Susvimo ranibizumab injection
Ryvu Announces Publication of Novel Target Discovery Data in Colorectal Cancer from the ONCO Prime Platform
Friday, August 01, 2025Ryvu Therapeutics a clinicalstage drug discovery and development company focused on novel therapies targeting emerging oncology indications announces the publication of data from its proprietary ONCO Prime target discovery
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Thursday, July 31, 2025Moderna Inctoday announced that the European Commission EC has granted marketing authorization for the updated formulation of the COVID vaccine Spikevax targeting the SARSCoV variant LP
Bayer submits registration applications for novel herbicide in four major markets
Wednesday, July 30, 2025Bayer advances its blockbuster pipeline submitting registration applications for icafolinmethyl in the European Union following completed applications in Brazil United States and Canada the company announced today
